Linfoadenectomia e nefrectomia citoriduttiva

Slides:



Advertisements
Similar presentations
Best Papers on Kidney Cancer Vincenzo Ficarra Direttore Clinica di Urologia Azienda Ospedaliera Universitaria di Udine.
Advertisements

PROSTATE CANCER Dr Samad Zare Assistant Proffesor of Urology Shaheed Sadoughi University of Medical Sciences.
An Intergroup Randomised Trial of Rituximab versus a Watch & Wait Approach in Patients with Advanced Stage, Asymptomatic, Non-bulky Follicular Lymphoma.
Regional Perspectives on Renal Cell Carcinoma Mohamed Abdulla M.D. Professor of Clinical Oncology Cairo University AfME. September 17 th 2010W:
Neoadjuvant Chemotherapy in Malignant Peripheral Nerve Sheath Tumors Elizabeth Shurell, M.D., M.Phil. UCLA General Surgery Resident Research Fellow, Division.
 DISCUSSION Number of resected lymph nodes in esophageal surgery has been previously discussed as for its probable impact on patients’ survival [4]. The.
Endometrial Cancer Surgical Staging (Role of Lymphadenectomy) Karl Podratz MD PhD FACS.
Renal Tumours n Mr C Dawson MS FRCS n Consultant Urologist n Fitzwilliam Hospital n Peterborough.
62 years old man Main complaint: Back pain at night but not during the day Loss of appettite Weight loss.
Management of T1 Kidney Cancer Laparoscopic Surgery
Total Lesion Glycolysis by 18 F-FDG PET/CT a Reliable Predictor of Prognosis in Soft Tissue Sarcoma Ilkyu Han Musculoskeletal Tumor Center, Seoul National.
Radiofrequency Ablation of Lung Cancer
IN THE NAME OF GOD.
Neoadjuvant Adjuvant Curative Palliative Neoadjuvant Radiation therapy the results of a phase III study from Beijing demonstrated a survival benefit.
Management of early rectal carcinoma Joint Hospital Surgical Grand Round Jeren Lim United Christian Hospital.
Controversies in the management of PSA-only recurrent disease Stephen J. Freedland, MD Associate Professor of Urology and Pathology Durham VA Medical Center.
A REVISIT TO MANAGEMENT OF GASTROINTESTINAL STROMAL TUMOUR (GIST) Joint Hospital Surgical Grand Round 17 Jan 2015 Grace Liu Pamela Youde Nethersole Eastern.
HCC Guidelines and recommendation Typical feature (wash in/wash out) New mass/nodule NoYes Alternative imaging technique Atypical featureTypical.
Linfoadenectomia e nefrectomia citoriduttiva Vincenzo Ficarra Associate Professor of Urology, University of Udine, Italy Associate Editor BJU International.
© Copyright 2003 Cardinal Health, Inc. or one of its subsidiaries. All rights reserved. PET in Colorectal Cancer Early detection of disease Precise Staging.
NECN Lung NSSG April 2012 Managing Solitary Brain Metastases from NSCLC Dr Paula Mulvenna Consultant Clinical Oncologist Northern Centre for Cancer Care.
In the name of God Isfahan medical school Shahnaz Aram MD.
A Phase II Study to Evaluate the Safety and Toxicity of Sparing Radiation to the Pathologic N0 Side of the Neck in Squamous Cell.
Clinical case HIGHLIGTHS IN ADVANCED RENAL CELL CARCINOMA MANAGEMENT Roma, 24 febbraio 2012 Cristina Masini Azienda Ospedaliero Universitaria Policlinico.
Are there benefits from chemotherapy to early endometrial cancer
Phase II Presurgical Feasibility Study of Bevacizumab in Untreated Patients with Metastatic Renal Cell Carcinoma Jonasch E et al. Journal of Clinical Oncology.
Prognostic factors and predictive models Vincenzo Ficarra Associate Professor of Urology, University of Padova, Italy Scientific Director OLV Robotic Surgery.
Background  Reports of long-term survivors (≥5 years) of locally advanced esophageal cancer (LAEC) have focused mainly on HRQL or GI symptoms  Only.
Current Role of Partial Cystectomy: Are we scarifying patient ’ s survival Dr Eric Li Department of Surgery Pamela Youde Nethersole hospital.
Renal cell cancer: Integrating novel agents into a therapeutic algorithm Robert Dreicer, M.D., FACP Chairman Department of Solid Tumor Oncology Taussig.
Sorveglianza attiva e trattamenti ablativi Vincenzo Ficarra Direttore Clinica di Urologia Azienda Ospedaliera Universitaria di Udine.
DISCUSSION AND CONCLUSION Alberto Briganti Urological Research Institute Vita Salute San Raffaele University Dept. of Urology, Milan, Italy.
TNM staging system for Renal Cell Carcinoma: current status and future perspectives Vincenzo Ficarra Dipartimento di Scienze Oncologiche e Chirurgiche.
THE OUTBACK TRIAL A Phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared.
“INTEGRAZIONE TRA TERAPIA CHIRURGICA E TERAPIA MEDICA” Camillo Porta, MD Medical Oncology I.R.C.C.S. San Matteo University Hospital Foundation, Pavia.
HCC Guidelines
Management of the primary in Stage IV colorectal cancer Erin Kennedy, MD, PhD, FRCSC Colorectal Surgery Mount Sinai Hospital University of Toronto.
Symptom control in patients with recurrent ovarian cancer Measuring the benefit of palliative chemotherapy in women with platinum refractory/ resistant.
Campbell’s & Literature review. Campbell 9 th & 10 th edition Cytoreductive nephrectomy  Palliation for: 1. Severe bleeding. 2. Pain. 3. Paraneoplastic.
Raafat R. Abdel-Malek, MD, FRCR Ass. Prof Clinical Oncology Cairo University, Egypt Efficacy & Toxicity of Sunitinib in mRCC patients in Egypt.
Radical Nephrectomy The Role Of Surgery In mRCC Peter Mulders Professor and Chairman Department of Urology University Medical Center Nijmegen The Netherlands.
Role of Sentinel Lymph Node Biopsy in the Staging of Synovial, Epithelioid, and Clear Cell Sarcomas. Ugwuji N. Maduekwe, Francis J. Hornicek, Dempsey S.
M ETHODS Median dose was 22Gy (range: ) in 1 to 5 fractions Median treatment volume was 12.6 cc (range: ). Assessed for eligibility.
Surgery of colorectal metastasis in the Optimox 1 study. A GERCOR Study. N. Perez-Staub, G. Lledo, F. Paye, B. Gayet, M. Flesch, A. Cervantes, A. Figer,
Anaplastic thyroid cancer based on ATA guideline for Management of Patients with ATC. Thyroid. 2012;22: R3 이정록.
Personalized medicine in lung cancer R4 김승민. Personalized Medicine in Lung Cancer patients with specific types and stages of cancer should be treated.
Renal cell carcinoma R4 신재령 Clinical Practice Guidelines for the Treatment of Metastatic Renal Cell Carcinoma.
Neoadjuvant treatment of borderline resectable and non-resectable pancreatic cancer V. Heinemann*, M. Haas & S. Boeck Annals of Oncology 24: 2484–2492,
Surgery for Metastatic Brain Tumor from Breast Cancer
KCR Spring Training T,N,M Case Examples Tonya Brandenburg.
Radical Prostatectomy versus Watchful Waiting in Early Prostate Cancer Anna Bill-Axelson, M.D., Lars Holmberg, M.D., Ph.D., Mirja Ruutu, M.D., Ph.D., Michael.
D2 Lymphadenectomy Alone or with Para-aortic Nodal Dissection for Gastric Cancer NEJM July vol 359 R2 임규성.
Renal cell carcinoma : alternative treatment LUKMAN HAKIM DEPARTMENT OF UROLOGY, AIRLANGGA UNIVERSITY/DR. SOETOMO GENERAL HOSPITAL.
Debulking in Ovarian Cancer Ashraf Fawzy Nabhan Assistant Prof. of Obstetrics & Gynecology Ain Shams University, Cairo, Egypt.
Long-term outcomes of combination of endoscopic submucosal dissection and laparoscopic lymph node dissection without gastrectomy for early gastric cancer.
Uro-Oncology Laparoscopic Surgery Wahjoe Djatisoesanto Department of Urology, School of medicine Airlangga University Soetomo General Hospital Surabaya.
Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal- cell carcinoma after radical nephrectomy: phase III,
Brain imaging prior to lung cancer resection
Karcinom rektuma- management
Lymph Node Dissection for Renal Cell Carcinoma: When, How and Why?
Results of Definitive Radiotherapy in Anal Canal Carcinoma
Surgical Treatment in Locally Advanced Prostate Cancer
1 LINFOADENECTOMIA Alessandro Volpe Università del Piemonte Orientale
Brain imaging prior to lung cancer resection
MANAGEMENT OF SMALL RENAL TUMORS: Current Evidence
Mahmood rasheed Hematology/oncology fellow VCU Massey cancer center
Lymph Node Dissection in Renal Cell Carcinoma
Dr T P E Wells 13 July 2018 Breast SSG Bath
SORVEGLIANZA ATTIVA DELLE PICCOLE MASSE RENALI
Treatment Overview: The Multidisciplinary Team
Presentation transcript:

Linfoadenectomia e nefrectomia citoriduttiva Vincenzo Ficarra Direttore Clinica di Urologia Azienda Ospedaliera Universitaria di Udine

Radical nephrectomy for RCC: the Robson criteria " ... to occlude the renal artery at an early stage of the procedure and remove the renal tumor en bloc with the lymphatics" "The para-aortic (left) and para-caval (right) lymph nodes should be removed from the crus of the diaphragm distally to the biforcation of the aorta". Robson CJ J Urol 1963; 89: 37-42

Lymphatic drainage of the Kidney and extended LND dissection

Template for extended LND dissection Crispen PL. et al. Eur Urol. 2011; 59: 18-23

Imaging techniques and nodal metastases staging The available technology is capable of accurately identifying only large lymph node metastases Patients with (micro)metastases in normal-sized nodes who might benefit from LND cannot be visualized by any of the available imaging techniques (US, CT, MRI) Capitanio U. et al. Eur Urol. 2011; 60: 1212-1220

Nomogram predicting hilar LNI in RCC (external validation) Accuracy: 78.4% Hutterer GC. et al. Int J Cancer 2007; 121: 2556-61

Role of extended LND in cN0 RCC: EORTC trial 30881 383 RN + extended LND 85 % 772 cases (T1-3, N0M0) 1. Expected 5-year survival rate 389 RN alone 70 % Blom JHM et al. Eur Urol. 2009; 55: 28-34

Role of extended LND in cN0 RCC: EORTC trial 30881 Blom JHM et al. Eur Urol. 2009; 55: 28-34

EORTC trial 30881: clinical characteristics * * TNM, 1978 Blom JHM et al. Eur Urol. 2009; 55: 28-34

EORTC trial 30881: Pathological characteristics * * TNM, 1978 Blom JHM et al. Eur Urol. 2009; 55: 28-34

Role of extended LND in M0 RCC: SEER database Sun M. et al. BJU Int 2014; 113: 36–42.

Pathological LNI prevalence according to pathological characteristics Capitanio U. et al. Eur Urol. 2011; 60: 1212-1220

High-risk clear cell RCC for LNI pT3-4 tumors Grade 3-4 Sarcomatoid dediff. Size >10 cm Coagulative necrosis Crispen PL. et al. Eur Urol. 2011; 59: 18-23

* Capitanio U. et al. BJU Inter. 2014; doi:10.1111/bju.12125

Accuracy 86.9% * Capitanio U. et al. BJU Inter. 2014; doi:10.1111/bju.12125

The use of a threshold of 3% would allow the avoiding of ~50% of the LNDs * Capitanio U. et al. BJU Inter. 2014; doi:10.1111/bju.12125

Rational algorithm for RCC patient candidates for LND Capitanio U. et al. Eur Urol. 2011; 60: 1212-1220

* Bekema HJ et al. Eur Urol. 2013; 64: 799-810

* Bekema HJ et al. Eur Urol. 2013; 64: 799-810

EORTC trial 30881: cT3-4 subanalysis * Blom JHM et al. Eur Urol. 2009; 55: 28-34

Lymph node dissection in locally advanced Renal Cell Carcinoma * Bekema HJ et al. Eur Urol. 2013; 64: 799-810

Lymph node dissection in locally advanced Renal Cell Carcinoma * Bekema HJ et al. Eur Urol. 2013; 64: 799-810

* There is insufficient evidence to draw any conclusions on oncologic outcomes for patients having concomitant LND compared with patients having RN alone for cT3–T4N0M0 RCC The quality of evidence is generally low and the results potentially biased. * Bekema HJ et al. Eur Urol. 2013; 64: 799-810

Rational algorithm for RCC patient candidates for LND Capitanio U. et al. Eur Urol. 2011; 60: 1212-1220

Role of extended LND in cN+ RCC

Role of extended LND in cN+M0 RCC Pantuck AJ J Urol 2003; 169: 2076-83

Role of LND in patients with distan metastases: fractional percentage of tumour volume removed However, not only an ideal cancer staging system should aid the clinician in the appropriate selection of therapeutic options but above all, in my opinion, it should stratify the patient’s risk of cancer progression or cancer death. Pierorazio PM et al BJU Inter 2007; 100: 755-759

Rational algorithm for RCC patient candidates for LND cT2b (>10 cm); N0 cT3-4; N0 cN+ M+

Russell CM et al. J Urol. 2014; (in press)

Isolated Nodal Recurrences Russell CM et al. J Urol. 2014; (in press)

Isolated Nodal Recurrences Russell CM et al. J Urol. 2014; (in press)

Isolated Nodal Recurrences Russell CM et al. J Urol. 2014; (in press)

Isolated Nodal Recurrences Surgical resection represents the best curative option for patients who present with isolated retroperitoneal lymph node recurrence of RCC Durable postoperative progression-free survival is attainable in many patients regardless of histology or clinical TNM stage Russell CM et al. J Urol. 2014; (in press)

Role of Nephrectomy in mRCC Curative (Nephrectomy + metastasectomy) Cytoreductive (To resect primary tumor in the prior to the initiation of systemic therapy for unresectable metastases) Palliative (To improve symptoms) - pain related to the kidney mass - intractable hematuria - paraneoplastic syndrome

Palliative Nephrectomy in mRCC 492/5378 (9.1%) cases surgically treated from 1995-2007 SATURN database – LUNA fundation (unpublished data)

Combined analysis (SWOG/EORTC) 13.6 months However, not only an ideal cancer staging system should aid the clinician in the appropriate selection of therapeutic options but above all, in my opinion, it should stratify the patient’s risk of cancer progression or cancer death. + 5.8 months 7.8 months Flanigan RC et al J Urol 2004; 171: 1071-1076

Combined analysis (SWOG/EORTC) Cytoreductive nephrectomy significantly improve overall survival in patients with mRCC treated with IFN-alpha independent of patients - performance status - site of metastasis (lung) - presence of measurable disease - (?) single Vs multiple metastases However, not only an ideal cancer staging system should aid the clinician in the appropriate selection of therapeutic options but above all, in my opinion, it should stratify the patient’s risk of cancer progression or cancer death. Flanigan RC et al J Urol 2004; 171: 1071-1076

Population-based assessment (SEER - 1988-2004) However, not only an ideal cancer staging system should aid the clinician in the appropriate selection of therapeutic options but above all, in my opinion, it should stratify the patient’s risk of cancer progression or cancer death. Zini L. et al Urology 2009; 73: 342-346

Guidelines on Renal Cell Carcinoma EAU, 2013 ESMO, 2010 NCCN, 2013 Palliative or complementary systemic treatments are necessary Recommended for mRCC patients with good PS when combined with IFN-alfa (Grade A) Only limited data are available addressing the value of CN combined with targeting agents Standard of cure in patients receiving cytokines [1, A] Role of CN needs to be re-evaluated in the present era of molecular targeted therapies Curative intent in patients with resectable solitary metastasis Cytoreductive intent in patients with good PS and without brain metastasis Role of CN and patients selection may warrant assessment in the setting of targeted therapies Palliative in symptomatic mRCC Gli obiettivi del nostro studio sono di… 42

Cytoreductive Nephrectomy in the era of Targeted molecular agents However, not only an ideal cancer staging system should aid the clinician in the appropriate selection of therapeutic options but above all, in my opinion, it should stratify the patient’s risk of cancer progression or cancer death.

A population-based study examining the role of nephrectomy prior to treatment However, not only an ideal cancer staging system should aid the clinician in the appropriate selection of therapeutic options but above all, in my opinion, it should stratify the patient’s risk of cancer progression or cancer death. Warren M. et al Can Urol Assoc J 2009; 3 (4): 281-89

Value of Cytoreductive Nephrectomy for mRCC in the Era of Targeted Therapy However, not only an ideal cancer staging system should aid the clinician in the appropriate selection of therapeutic options but above all, in my opinion, it should stratify the patient’s risk of cancer progression or cancer death. Choueiri TK. et al J Urol 2011; 185: 60-66

Value of Cytoreductive Nephrectomy for mRCC in the Era of Targeted Therapy CN: 20% sarcomatoid features Non CN: 3% sarcomatoid feature Sarcomatoid feature: HR 2.7 (1.2-6.7) However, not only an ideal cancer staging system should aid the clinician in the appropriate selection of therapeutic options but above all, in my opinion, it should stratify the patient’s risk of cancer progression or cancer death. You D. et al J Urol 2011; 185: 54-59

Ideal candidate for cytoreductive nephrectomy MD Anderson: 470 CN and 88 medical therapy only Lactate dehydrogenase Albumin level Symptoms (S3) Liver metastasis N+ retroperitoneal N+ supradiaphragmatic ≥ T3 However, not only an ideal cancer staging system should aid the clinician in the appropriate selection of therapeutic options but above all, in my opinion, it should stratify the patient’s risk of cancer progression or cancer death. Culp SH et al Cancer 2010; 116: 3378-88

Candidate for cytoreductive nephrectomy Good surgical risk (good performance status) Limited metastatic tumor burden to lung or bone Extensive metastatic disease with systemic therapy planned Symptoms related to the primary tumor However, not only an ideal cancer staging system should aid the clinician in the appropriate selection of therapeutic options but above all, in my opinion, it should stratify the patient’s risk of cancer progression or cancer death. NCCN Guidelines, 2013

CARMENA (NCT00930033) Trial Study start data: May 2009 – Estimated Study completition: May 2013 Eligibility Criteria ECOG PS of 0 or 1 Clear cell histology Resectable primary tumour No prior systemic treatment Adequate organ function Cytoreductive Nephrectomy + Sunitinib (N=576) Randomization Sunitinib alone Primary endpoint: Overall Survival Secondary endpoints: Objective response, PFS, Safety Hopitaux de Paris and Pfizer – www.clinicaltrials.gov

SURTIME (EORTC 30073) Trial Study start data: April 2010 – Estimated Study completition: October 2014 Eligibility Criteria Clear cell histology Resectable primary tumour Asymptomatic primary tumour Measurable disease No prior systemic treatment Adequate organ function Sunitinib (3 course) + Deferred CN (N= 458) Randomization Immediate CN + Sunitinib (3 course) Primary endpoint: Overall Survival Secondary endpoints: Objective response, PFS, Safety Hopitaux de Paris and Pfizer – www.clinicaltrials.gov

Conclusions Nephrectomy is still an important part of the multidisciplinary treatment of RCC Targeted agents represent a substantial improvement but since they are not curative, the cytoreductive paradigm is still relevant Today, the more relevant question should address the timing of and appropriate patient selection for cytoreductive nephrectomy However, not only an ideal cancer staging system should aid the clinician in the appropriate selection of therapeutic options but above all, in my opinion, it should stratify the patient’s risk of cancer progression or cancer death.